DrugNot recommended line

Rituximab

Anti-CD20 (B-cell depletion)

Response rate
Ineffective on inflammation
Onset
—
Route
IV infusion
Line
Not recommended
IgM effect
Reduces IgM
Evidence level
red

Evidence summary

Depletes B cells and can reduce IgM, but doesn't control inflammatory symptoms.

Molecular targets

MoleculeRoleExpressionEvidence
IgM (monoclonal)Diagnostic paraproteinPresent (obligate)established

Sources (2)

A5de Koning HD (2014) Comprehensive review (281 cases)DOI ↗
J5Braud A et al. (2024) Most recent comprehensive reviewDOI ↗